치료 경험이 없는 황반부 망막색소상피박리에서 브롤루시주맙 주사의 단기 효과: 증례보고 (Short-term Efficacy of Brolucizumab in Treatment-naïve Large Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration: Case Report)

서지정보

· 발행기관 : 한국망막학회
· 수록지 정보 : Journal of Retina / 9권 / 2호 / 210 ~ 214페이지
· 저자명 : 송지은, 정영훈

초록

Purpose: To report short-term efficacy of brolucizumab injection in treatment-naïve large pigment epithelial detachment secondary to neovascular age-related macular degeneration.
Case Summary: A 63-year-old male presented with decreased visual acuity in the left eye. He was diagnosed with neovascular age-related macular degeneration accompanied by large pigment epithelial detachment (PED), with central retinal thickness (CRT) of 641 μm and best-corrected visual acuity (BCVA) of 0.3 (decimal). Two months later, without treatment, the PED had worsened, with CRT of 782 μm and BCVA of 0.2. Considering the rapid progression of the PED and the deterioration in visual acuity, intravitreal brolucizumab injection was administered. One month after the injection, significant improvement was observed, with CRT of 246 μm and BCVA of 1.0. The improvement was maintained at the three-month follow-up, with resolution of the PED and subretinal fluid and sustained BCVA of 1.0.
No ocular inflammation or occlusive retinal vasculitis was observed during follow-up.
Conclusions: This case demonstrates the short-term efficacy of brolucizumab injection in a treatment-naïve patient with neovascular age-related macular degeneration, presenting with a rapidly progressing large pigment epithelial detachment and associated visual loss.

영어초록

Purpose: To report short-term efficacy of brolucizumab injection in treatment-naïve large pigment epithelial detachment secondary to neovascular age-related macular degeneration.
Case Summary: A 63-year-old male presented with decreased visual acuity in the left eye. He was diagnosed with neovascular age-related macular degeneration accompanied by large pigment epithelial detachment (PED), with central retinal thickness (CRT) of 641 μm and best-corrected visual acuity (BCVA) of 0.3 (decimal). Two months later, without treatment, the PED had worsened, with CRT of 782 μm and BCVA of 0.2. Considering the rapid progression of the PED and the deterioration in visual acuity, intravitreal brolucizumab injection was administered. One month after the injection, significant improvement was observed, with CRT of 246 μm and BCVA of 1.0. The improvement was maintained at the three-month follow-up, with resolution of the PED and subretinal fluid and sustained BCVA of 1.0.
No ocular inflammation or occlusive retinal vasculitis was observed during follow-up.
Conclusions: This case demonstrates the short-term efficacy of brolucizumab injection in a treatment-naïve patient with neovascular age-related macular degeneration, presenting with a rapidly progressing large pigment epithelial detachment and associated visual loss.

참고자료

· 없음